Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate i… (NCT05767346) | Clinical Trial Compass
CompletedPhase 3
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
United States, Brazil, Canada175 participantsStarted 2023-06-20
Plain-language summary
The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succinate in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction
Who can participate
Age range
18 Years – 85 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. ≥ 15 mm in one or more myocardial segments OR
. ≥ 13 mm in one or more wall segments and a known disease-causing gene mutation or positive family history of HCM
Exclusion criteria
. Moderate-severe valvular aortic stenosis or fixed subaortic obstruction
. Mitral regurgitation not due to systolic anterior motion of the mitral valve (per Investigator judgment)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this is a Phase 3 trial comparing aficamten directly to metoprolol succinate — a beta-blocker already used for oHCM — how does what's been learned from this completed trial change your thinking about whether aficamten or metoprolol would be the better option for my specific situation?
2The trial measured improvement in peak oxygen uptake during exercise testing — what does my current exercise capacity look like, and would that kind of measurement help us track whether any treatment is actually working for me?
3Now that this trial is completed, is the full safety and efficacy data available, and are there any side effects or risks from aficamten that showed up in the results that I should know about before considering it?
4Given that metoprolol succinate was the comparator in this trial and is already an established treatment for oHCM, would it make more sense for me to try standard therapy first before exploring newer options like aficamten?
5Is aficamten approved or available outside of a clinical trial at this point, or would participating in a different study be the only way I could access it if we decided it might be right for me?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)